Onlab BioHealth Dementia Innovation Challenge – Application Closed.
Thank you for your applications.
Open Office Hours
Open Office Hours are available for the startups and entrepreneurs.
We are having one-on-one meetings with our team to discuss ideas and business strategies.
Open Network Lab BioHealth, which has been supporting the growth of startups in the biotechnology and healthcare fields,
is holding the “Open Network Lab BioHealth Dementia Innovation Challenge” with Eisai Co., Ltd.
This program will promote open innovation between dementia-related startups, Eisai and Digital Garage,
and contribute to the actualization of a Dementia Inclusive Society through technology and science.
Maintaining good health through information management and advance prediction of dementia risk.
Promoting the understanding and prevention of dementia through disease prediction, disease awareness, and simple and accurate testing.
Promoting accurate diagnosis of MCI and early dementia and its efficiency, as well as rapid efficacy assessment and monitoring of side effects.
Updating the treatment of dementia through drug discovery, medical equipment and digital devices.
Supporting the lives of dementia patients and their families.
Solving a variety of problems directly or indirectly related to dementia (finance, real estate, insurance, etc.).
#Any other technologies or services that fall under the theme are welcome to apply.
There are two types of this program;
The Open Innovation Program is to aim for collaborative business development, business tie-up, and equity investment by combining the technologies and services of startups with the resources of Eisai and Digital Garage, examining ideas for collaboration and testing hypotheses through PoC study; Accelerator program is to provide support for seed and early-stage startups to grow their businesses through mentoring by the specialists.
*The program is subject to change according to the situation and needs of the participating startups.
Experienced professionals in business development and collaboration in drug creation and digital business will work closely with the participating startups to support open innovation management, hypothesis validation, product brush-ups, and pitch practice.
Eisai and Digital Garage will support the participating startups by utilizing our resources. We will also collaborate and cooperate in various aspects of toward business creation, including PoC study and Business tie-up.
Eisai and Digital Garage may each consider equity investment to the participating startups based on the needs. *Note that the participation of this program does not guarantee equity investment.
Eisai, which has numerous accomplishments and experiences in the field of dementia including drug creation, and Digital Garage, which is strong in business support and investment activities for startups including Onlab, will collaborate to support the growth of startups’ businesses in the field of dementia.
External experts are also available to provide support as needed.
Each startup has different needs for support, such as “I want to see if our service can collaborate with you”, “I want to work with you to develop a business using our technology,” or “I want you to provide an environment for PoC”. In this program, we flexibly provide support to achieve each startup’s purposes and goal.
This program provides support by the appropriate departments and talents from Eisai and Digital Garage toward collaboration.
Chief Ecosystem Officer
Member, Board of Directors
* Please note that changes of the contents may be made due to the impacts of COVID-19 or other reasons.
*The application deadline has been extended from December 27 to January 17, and the selection and program period have been postponed.
Director, Representative Corporate Officer and CEO
In the 1990s, Eisai developed and launched ARICEPT®, an Alzheimer’s disease (AD) treatment, and started delivering it to patients, having make it available in 101 countries worldwide. From them onward, to help us understand and learn the true thoughts and feelings of patients, Eisai encourages all of its employees globally to spend at least 1% of their total business hours with patients, so called Socialization activities. In 2021, Eisai launched ADUHELM®, the first drug that works by reducing amyloid plaques, one of the causative factors of AD, in the United States with Biogen. By leveraging accumulated lessons learned from many failures over the past quarter century, Eisai has been now working on development of novel drug candidates that fundamentally address the underlying cause of AD.
Alzheimer’s is a disease that places enormous burden on people living with the disease and their families, and we recognize how deep their anxieties are. Alzheimer’s begins years or even decades before any symptoms appear. Therefore, it is important for all People to not only have knowledge and awareness about lifestyle considerations, but also improve access to disease information. In addition, health-related information gained from the People can also provide a wide variety of advices and insights based on data analysis that in turn can further help the People live healthier. In line with this, Eisai is planning to develop an ecosystem where individuals and various industries can work together to support the People to “live life to the fullest.” We believe that building this type of the ecosystem should be a top priority, and by combining the vast knowledge gained through our history of drug creation activities with new knowledge from startups and technology companies, we can help the People live their lives to the fullest. We look forward to working with you through this program.
|Program||Open Network Lab BioHealth Dementia Innovation Challenge|
|Terms of Participation||
Please contact us for any questions other than the above.
We will send you the latest events information and articles
or notify opening of application for each Onlab's Program, and more.